Ngwaahịa

Oke oke ibu, ụdị ọrịa shuga 2 na hyperlipidemia na-ebikọ ọnụ ma na-ejikọta ya na ọrịa na-anwụ anwụ nke ukwuu.Oriri carbohydrate a nụchara anụcha na ọkachasị fructose abawanyela nke ukwuu n'afọ ndị na-adịbeghị anya ma mee ka mmụba nke oke ibu na ọrịa shuga na-abawanye.Ọmụmụ mmadụ na anụmanụ egosila na oriri fructose dị elu na-ejikọta ọnụ na ụbara dyslipidemia, nguzogide insulin, na ọbara mgbali elu.Metabolism nke fructose na-apụta n'ụzọ bụ isi na imeju na fructose dị elu na-eduga n'ịba ụba mkpokọta triglyceride imeju (hepatic steatosis).Nke a na-ebute mbelata glucose na metabolism lipid yana mmụba cytokine proinflammatory.N'ebe a, anyị na-egosi na fructose na-agbanwe okwu mkpali glucose nke acetyl CoA carboxylase (ACC) na-arụ ọrụ, pSer hormone kókó lipase (pSerHSL) na adipose triglyceride lipase (ATGL) na HepG2 imeju ma ọ bụ omenala hepatic cell in vitro.Ejikọtara nke a na mmụba nke de novo triglyceride synthesis in vitro na hepatic steatosis in vivo in fructose- versus glucose- feeded and standard-nri nri ụmụ oke.Ọmụmụ ihe ndị a na-enye nghọta ọhụrụ banyere usoro ndị metụtara fructose-mediated hepatic hypertriglyceridemia ma chọpụta nnabata fructose dị ka ebumnuche ọgwụgwọ ọhụrụ maka ọrịa ndị metụtara lipid.